NDV01 intravesical controlled release formulation of gemcitabine and docetaxel
REL-NDV01-011
Phase 2 small_molecule active
Quick answer
NDV01 intravesical controlled release formulation of gemcitabine and docetaxel for Non Muscle Invasive Bladder Cancer is a Phase 2 program (small_molecule) at RELMADA THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- RELMADA THERAPEUTICS, INC.
- Indication
- Non Muscle Invasive Bladder Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active